COPD and tobacco smoke

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 63, Issue 4, 2005, Pages 213-225

  Bartal, Mohamed ^a  

^a Moroccan Society of Allergology and Clinical Immunology   (Morocco)

Author keywords

COPD; Lung function; Smoking; Smoking cessation; Tobacco

Indexed keywords

ANTIOXIDANT; OXIDIZING AGENT; PROTEINASE; PROTEINASE INHIBITOR; TOBACCO SMOKE;

ACUTE DISEASE; ADVENTITIA; ASTHMA; BRONCHUS MUCUS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DETERIORATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; EXPOSURE; EXTRACELLULAR MATRIX; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LUNG ALVEOLUS WALL; LUNG BLOOD VESSEL; LUNG FIBROSIS; LUNG FUNCTION; LUNG PARENCHYMA; MORBIDITY; MORTALITY; PASSIVE SMOKING; POPULATION RESEARCH; PRENATAL EXPOSURE; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR; SMOKING CESSATION; SMOOTH MUSCLE; SUBMUCOSA; TOBACCO DEPENDENCE;

EID: 31744445139     PISSN: 11220643     EISSN: 2465101X     Source Type: Journal    
DOI: 10.4081/monaldi.2005.623     Document Type: Review

References (155)

1. Global Initiative for Chronic Obstructive Disease. Global Strategy for The Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Workshop Report. National Institutes of Health, National Heart, Lung, and Blood Institute. Publication No. 2701, April 2001. Update of the management sections, GOLD web site www.goldcopd.com.
2. US Department of Health and Human Services. The health consequences of smoking: chronic obstructive lung disease. Washington DC, US Government Printing Office, 1984; D1-HIS (PHS) 84-50205.
3. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world. Global burden of disease, 1990-2020. Nat Med 1998; 4: 1241-3.
4. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause, 1990-2020. Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
5. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000; 117 (Suppl): 1S-4S.
6. Sullivan SD, Ramsey SD, and Lee TA. The economic burden of COPD. Chest 2000; 117 (Suppl): 5S-9S.
7. World Health Organization. The World Health Report1999: making difference. Geneva, Switzerland: World Health Organization, 1990.
8. Murray CJL, Lopez AD, eds. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press. 1996.
9. Murray CJL, Lopez AD. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 1996; 274: 740-3.
10. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123: 1684-92.
11. Fletcher CM, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-8.
12. Menotti A, Blackburn H, Seccariccia F, et al. The relation of chronic disease to all-cause mortality risk. The Seven Countries Study. Ann Med 1997; 29: 135-41.
13. Anthonisen NR. Prognosis in chronic obstructive pulmonary disease. Eur Respir Rev 1995; 5, 31: 310-4.
14. Bakke PS, Hanoa R, Gulsvik A. Educational level and obstructive lung disease given smoking habit and occupational airborne exposure: a Norvegian community study. Am J Epidemiol 1995; 141: 1080-8.
15. Prescott E, Lange P, Vestbo J, and the Copenhagen City Heart Study Group. Socieconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J 1999; 13: 1109-14.
16. Feenstra TL, van Genugten MLL, Hoogenveen RT, Wouters EF, and Rutten-van Molken MPMH. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease. A model analysis in the Netherlands. Am J Respir Crit Care Med 2001; 164: 590-6.
17. Aït Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull WHO 2001; 79 (10): 971-9.
18. US Department of Health and Human Services. The Health Benefits of Smoking Cessation. A report of the Surgeon General. US Government Printing Office, Washington, DC. 1990.
19. Buist AS. Risk factors for COPD. Eur Repir Rev 1996; 6,39: 253-8.
20. US Department of Health and Human Services. Reducing the consequences of smoking: 25 years of progress. A report of the Surgeon General. Rockville, MD, Department of Health and Human Services, Public Health Services, 1989.
21. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationship between cigarette smoking and ventilatory function. Am Rev Respir Dis 1977; 115: 195-205.
22. Holland WW. Chronic obstructive pulmonary disease prevention. Br J Dis Chest 1988; 82: 32-44.
23. Tashkin PD, Detels R, Simmons M, Liu H, and Coulson AH, Sayre J, Rokaw S.The UCLA population studies of chronic obstructive pulmonary disease: XI.Impact of air pollution and smoking on annual change in forced expiratory volume in one seconde. Am J Rerspir Crit Care Med 1994; 149: 1209-17.
24. Becklake MR, Lalloo U. The "healthy smoker": A phenomenon of health selection? Respiration 1990; 57: 137-44.
25. 1: New insight into gender differences. Eur Respir J 1994; 7: 1056-61.
26. Lange P, Groth S, Nyboe J, et al. Decline of the lung function related to the type of tobacco smoked and inhalation. Thorax 1990; 45: 22-6.
27. Turpin L, Earnest G, San Pedro M, Balmes JR, Eisner MD, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003; 22, 3: 462-9.
28. Becklake MR. Occupational exposures: evidence for a causal association with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140: S89-91.
29. Kauffman F, Drouet D, Lellouch J, Brille D. Twelve years spirometric changes among Paris area workers. Int J Epidemiol 1979; 8: 201-12.
30. Lebowitz MD. Epidemiologic studies of the respiratory effects of air pollution. Eur Respir J 1996; 9: 1029-54.
31. Bascom R. Differential susceptibility to tobacco smoke: possible mechanisms. Pharmacogenetics 1991; 1: 102-28.
32. Lundback B, Lindberg A, Lindstrom M, et al. Not 15% but 50% of smokers develop COPD? Report from the obstructive lung disease in Northern Sweden studies. Respir Med 2003; 97: 115-22.
33. Silverman EK, Chapman HA, Drazen JM, et al. Genetic epidemiolgy of severe, early-onset chronic obstructive pulmonary disease: risk to relatives for airway obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998; 157: 1770-8.
34. Silverman EK, Speizer FE. Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am 1996; 80: 501-22.
35. Chen Y. Genetics and pulmonary medecine.10: Genetic epidemiology of pulmonary function. Thorax 1999; 54: 818-24.
36. Carrozi L, Rijcken B, Burney P, DeGraaf A, Angino A, et al. Family history for chronic lung diseases and epidemiological determinants of COPD in three European countries. Eur Respir Rev 2001; 11, 80: 49-54.
37. Barnes PJ. Chronic obstructive pulmoanry disease. N Engl J Med 2000; 343, 4: 269-80.
38. Stanford AJ, Weir TD, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 1380-91.
39. Buist AS, Vollmer WM, Wu Y, et al. Effects of cigarette smoking on lung function in four population samples in the People's Republic of China. Am J Respir Crit Care Med 1995; 151: 1393-400.
40. Coultas DB, Gong H Jr, Grad R, et al. State of the art: respiratory disease in minorities of the United States. Am J Respir Crit Care Med 1993; 149: S93-131.
41. Tarjan E, Magyar P, Vaczi Z, Vaszar L. Longitudinal lung function study in heterozygous PiMZ phenotype subjects. Eur Respir J 1994; 7: 2199-204.
42. Antó JM, Vermeire P, Sunyer J. Chronic obstructive pulmonary disease. ERS Monograph edited by I. Annesi-Maesano, A. Gulsvik, G. Viegi: Respiratory Epidemiology in Europe 2000; 15, 5: 1-22.
43. Camilli AE, Burrows B, Knudson RJ, Lyle SK, Lebowitz MD. Longitudinal changes in forced expiratory volume in one second in adults: effects of smoking and smoking cessation. Am Rev Respir Dis 1987; 135: 794-9.
44. Prescott E, Bjerg AM, Andersen PK, Lange P, Vestbo J. Gender difference in smoking effects on lung function and risk for hospitalization for COPD. Results from a Danish longitudinal population study. Eur Respir J 1997; 10: 822-7.
45. Chen Y, Horn SL, Dosman JA. Increased susceptibility to lung dysfunction in female smokers. Am Rev Respir Dis 1991; 143: 1224-30.
46. Leynaert B, Bousquet J, Henry C, Liard R, Neukirch F. Is Bronchial hyperresponsiveness more frequent in women than in men? A population-based study. Am J Respir Crit Care Med 1997; 156: 1413-20.
47. Xu X, Li B, Wang L. Gender differences in smoking effects on adult pulmonary function. Eur Respir J 1994; 7: 477-83.
48. 1. The Lung Health Study. JAMA 1994; 272: 1497-505.
49. Chailleux E, Laaban JP, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest 2003; 123: 1460-6.
50. Prescott E, Godtfredsen N, Vestbo J, Osler M. Social position and mortality from respiratory diseases in males and females. Eur Respir J 2003; 21: 821-6.
51. Buist AS, Connett JE, Miller RD, Kanner RE, Owens GR, Woelker HT. Chronic Obstructive Pulmonary Disease Early Intervention Trial (Lung Health Study). Chest 1993; 103: 1863-72.
52. Jaakkola MS. Environmental tobacco smoke and respiratory diseases. ERS Monograph edited by I. Annesi-Maesano, A. Gulsvik, G. Viegi: Respiratory Epidemiology in Europe 2000, 15, 5: 322-83.
53. US Environmental Protection Agency. Respiratory health effects of passive smoking: lung cancer and other disorders. US Environmental Protection Agency, Office of Health and Environmental Assessment, Office of Research and Development. Washington DC, 1992. EPA/600/6-90/006F.
54. Lodrup Carlsen KC, Jaakkola JJK, Nafstad P, Carlsen KH. In utero exposure to cigarette smoking influences lung function at birth. Eur Respir J 1997; 10: 1774-9.
55. von Ehrenstein OS, von Mutius E.S. Smoking and the lung. ERS Monograph edited by A. Bush, K-H. Carlson, M.S. Zach: Growing up with lung disease: the lung in transition to adult life 2001; 19, 7: 60-80.
56. Hanrahan JP, Tager IB, Segal MR, et al. The effect of maternal smoking during pregnancy on early infant lung function. Am Rev Respir Dis 1992; 145: 1129-35.
57. Tager IB, Ngo L, Hanrahan JP. Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. Am J Respir Crit Care Med 1995; 152: 977-83.
58. Upton MN, Watt GC, Smith GD, McConnachie A, Hart CL. Permanent effects of maternal smoking on offsprings' lung function. Lancet 1998; 352: 453.
59. Strachan DP, Seagroatt V, Cook DG. Chest illness in infancy and chronic respiratory disease in later life: an analysis by month of birth. Int J Epidemiol 1994; 23: 1060-8.
60. Tager IB, Weiss ST, Munoz A, Rosner B, Speiser F. Longitudinal study of the effects of maternal smoking on pulmonary function in children. N Engl J Med 1983; 309: 699-703.
61. Wang X, Wypij D, Gold DR, et al. A longitudinal study of the effects of parental smoking on pulmonary function in children aged 6-18 years. Am J Respir Crit Care Med 1994; 149: 1420-5.
62. Cook DG, Strachen DP, Carey IM. Parental smoking and spirometric indices in children. Thorax 1998; 53: 844-93.
63. Svanes C, Omenaas E, Jarvis D, Chinn S, Gulsvik A, Burney P. Parental smoking in childhood and adult obstructive lung disease: results from the European Community Respiratory Health Survey. Thorax 2004; 59: 295-302.
64. Tager IB, Segal MR, Munoz A, Weiss ST, Speizer FE. The effects of maternal smoking on the pulmonary function of children and adolescents. Analyses of data from two populations. Am Rev Respir Dis 1987; 136: 1366-70.
65. Ng TP, Hui KP, Wan C Tan. Respiratory symptoms and lung function effects of domestic exposure to tobacco smoke and cooking by gas in nonsmoking women in Singapore. J Epidemiol Commun Health 1993; 47: 454-9.
66. Wu X, Li B. Exposure-response relationship between passive smoking and adult pulmonary function. Am J Respir Crit Care Med 1995; 151: 41-6.
67. Jaakkola MS. Environmental tobacco smoke and health in the elderly. Eur Respir J 2002; 19: 172-81.
68. Robins AS, Abbey DE, Lebowitz MD. Passive smoking and chronic respiratory symptoms in nonsmoking adults. Int J Epidemiol 1993; 22: 809-17.
69. Lee PN, Chamberlain J, Alderson MR. Relationship of passive smoking and lung cancer and other smoking-associated diseases. Br J Cancer 1986; 54: 97-105.
70. Matsuse T, Hayashi S, Kazuyoshi K, Keunecke H, Jefferies WA, Hogg JC. Latent adenal viral infection in the pathogenesis of chronic airways obstruction. Am Rev Respir Dis 1992; 146: 177-84.
71. Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. Chest 2000; 117, 5: 251S-260S.
72. Barnes PJ. Mechanisms in COPD. Differences from asthma. Chest 2000; 117, 2 (Suppl): 10S-14S.
73. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-α induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care 1996; 153: 530-4.
74. Pesci A, Balbi B, Majori M, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 12: 380-6.
75. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995; 152: 1666-72.
76. 1. Am J Respir Crit Care Med 1997; 155: 852-7.
77. Saetta M, Di Stephano A, Turato G, et al. CD 8+ T lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 822-6.
78. Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997; 112: 505-10.
79. Barnes PJ, Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
80. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999; 160: 893-8.
81. Keatings VM, Barnes PJ. Comparison of inflammatory cytokines in chronic obstructive pulmonary diseases, asthma and controls. Eur Respir Rev 1997; 7: 146-50.
82. Pesci A, Majori M, Cuomo A, et al. Neutrophils infiltrating bronchial epithelium in chronic obstructive pulmonary disease. Respir Med 1998; 92: 863-70.
83. Peleman RA, Rytila PH, Kips JC, Joos GF, Pauwels RA. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 839-43.
84. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997; 155: 449-53.
85. Liu AN, Mohamed AZ, Rice WR, et al. Perforin-independent CD8(+) T cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand. Am J Respir Cell Mol Biol 1999; 20: 849-58.
86. Turato G, Di Stefano A, Maestrelli P, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995; 152: 1262-7.
87. Rutger SR, Postma DS, ten Hacken NE, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12-8.
88. Chanez P, Springall D, Vignola AM, et al. Bronchial mucosal immunoreactivity of sensory neuropeptides in severe airway diseases. Am J Respir Crit Care Med 1998; 158: 985-90.
89. Shapiro SD. Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential role in destructive lung disease. Am J Respir Crit Care Med 1994; 150: S160-4.
90. Finlay GA, O'Driscoll LR, Russel KL, et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997; 156: 240-7.
91. Hoidal JR, Jeffery PK. Cellular and biochemical mechanisms in chronic obstructive pulmonary disease. ERS Monograph edited by D.S. Postma, N.M. Siafakas: Management of chronic obstructive pulmonary disease 1998, 7, 3: 84-91.
92. Betsuyaku T, Nishimura M, Takeyabu K, et al. Neutrophyl granule ptoteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med 1999; 159: 1985-91.
93. Culprit SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1635-9.
94. Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, et al. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol 1999; 20: 729-36.
95. Saetta M, Turato G, Baraldo S, et al. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med 2000; 161: 1016-21.
96. Nadel JA. Role of neutrophyl elastase in hypersecretion during COPD exacerbation, and proposed therapies. Chest 2000; 117: 386S-389S.
97. Suk B, Lutchen KR, Ingenito EP. On the progressive nature of emphysema. Role of proteases, inflammation, and mechanical forces. Am J Respir Crit Care Med 2003; 168: 516-21.
98. Hirano K, Sakamoto T, Uchida Y, et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 2001; 18: 748-52.
99. Behr J, Nowak D. Tobacco smoke and respiratory disease. ERS Monograph edited by G. D'Amato and S.T. Holgate: The Impact of Air Pollution on Respiratory Health 2002; 21,7: 161-799.
100. Church DF, Pryor WA. Free-radical chemistery of cigarette smoke and its toxicological implications. Environ Health Perspect 1985; 64: 111-26.
101. Repine JE, Bast A, Lankhorst I, and the Oxidative Stress Study Group. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 341-57.
102. MacNee W. Oxidants-Antioxidants and COPD. Chest 2000; 117, 5: 303S-317.
103. Dekhuijzen PN, Aben KK, Dekker I, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154: 813-6.
104. Buhl R, Meyer A, Vogelmeier C. Oxidant-protease interaction in the lung. Prospects for antioxidant therapy. Chest 1996; 110: 267s-272s.
105. Mattana J, Margiloff L, Scharma P, Singal PC. Oxidation of the mesengial matrix metalloproteinase-2 impairs gelatinolytic activity. Inflammation 1998; 22: 269-97.
106. Lannan S, Donaldson K,Brown D, et al. Effects of cigarette smoke and its condensates on alveolar cell injury in vitro. Am J Physiol 1994; 266: L92-100.
107. Rahman I, Li WY, Donaldson K, et al. Cigarette smoke glutathione metabolism and epithelial permeability in rat lungs. Biochem Soc Trans 1995; 23: 235s.
108. Watchorn T, Mulier B, MacNee W. Does increasing intracellular glutathione inhibit cytoxine-induced nitric oxide release and NF-Kb activation. Am J Respir Crit Care Med 1998; 157: A889.
109. Cantin AM, Begin R. Glutathione and inflammatory disorders of the lung. Lung 1991; 169: 123-38.
110. Rahman I, MacNee W. Oxidative stress and regulation of the glutathione in lung inflammation. Eur Respir J 2000; 16: 535-54.
111. Mazzetti A, Lapenna D, Pierdominico SD, et al. Vitamins E, C, and lipid peroxidation in plasma and arterial tissue of smokers and nonsmokers. Atherosclerosis 1995; 112: 91-9.
112. Nishio E, Watanabe Y. Cigarette smoke extract is a modulator of mitogenic action in vascular smooth muscle cells. Life Sci 1998; 62: 1339-47.
113. Wright JL, Tai H, Dai J, Churg A. Cigarette smoke induces rapid changes in gene expression in pulmonary arteries. Lab Invest 2002; 82: 1391-8.
114. Rabe KF, Dent G, Magnussen H. Hydrogen peroxide contracts human airways in vitro: role of epithelium. Am J Physiol (Lung Cell Mol Physiol) 1995; 269: L332-8.
115. Wang H, Liu X, Umino T, Skold GM, Zhu Y, et al. Cigarette smoke inhibits human bronchial epithelial cell repair process. Am J Respir Cell Mol Biol 2001; 25: 772-9.
116. Carnevali S, Nakamora Y, Mio T, et al. Cigarette smoke extract inhibits fibroblast-mediated collagen gel contraction. Am J Physiol 1998; 247-L591-8.
117. Rennard SI. Inflammation and repair process in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160-S12-6.
118. Peinado VI, Barbera JA, Abate P, et al. Inflammation reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1605-11.
119. Sekhon HS, Wright JL, Churg A. Cigarette smoke causes rapid cell proliferation in small airways and associated pulmonary arteries. Am J Physiol 1994; 267: L557-63.
120. Weiss ST. Early life predictors of adult chronic obstrucive pulmonary disease. Eur Respir Rev 1995; 5, 31: 303-9.
121. Tager IB, Segal MR, Speizer FE, Weiss ST. The natural history of forced expiratory volumes: effect of cigarette smoking and respiratory symptoms. Am Rev Respir Dis 1988; 138: 837-49.
122. Sherril DL, Camilli A, Lebowitz MD. On the temporal relationship between lung function and somatic growth. Am Rev Respir Dis 1989; 140: 638-44.
123. Rijcken B, Britton J. Epidemiolgy of chronic obstructive pulmonary disease. ERS Monograph edited by D.S. Postma, N.M. Siafakas: Management of chronic obstructive pulmonary disease 1998; 7, 3: 41-73.
124. Burrows B. Airway obstructive diseases: pathogenic mechanisms and natural histories of the disorders. Med Clin North Am 1990; 74: 547-60.
125. Burrows B. Predictors of loss of lung function and mortality in obstructive lung diseases. Eur Respir Rev 1991; 1: 340-5.
126. Postma DS, Vermeire P. The natural history of chronic obstructive pulmonary disease. ERS Monograph edited by D.S. Postma, N.M. Siafakas: Management of chronic obstructive pulmonary disease 1998; 7, 3: 74-83.
127. Burrows B, Knudson RJ, Camilli AE, Lyle SK, Lebowitz MD. The "horse racing effect" and predicting decline in forced, expiratory volume in one second from screening spirometry. Am Rev Respir Dis 1987; 135: 788-93.
128. Tager IB, Weiss ST, Munoz A, Rosner B, Speizer F. Longitudinal study of the effects of maternal smoking on pulmonary function in children. N Engl J Med 1983; 309: 699-703.
129. Tager IB, Munoz A, Rosner B, Weiss ST, Carey V, Speirez FE. Effect of cigarette smoking on the pulmonary function of children and adolescents. Am J Respir Dis 19985; 131: 752-9.
130. Rijcken B, Schouten JP, Weiss ST, Speizer FE, VanderLende R. The relationship between airways responsiveness to histamine and pulmonary function level in a random population sample. Am Rev Respir Dis 1988; 137: 826-32.
131. Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease exacerbation. Eur Respir J 1999; 13: 343-8.
132. Monso E, Rosell A, Bonet G, et al. Risk factors for lower airway bacterial colonization in chronic bronchitis. Eur Respir J 1999; 13: 338-42.
133. Miravittles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J 2002, Suppl. 36: 9s-19s.
134. Mio T, Romberger DJ, Thompson AB, Robbins RA, Heires A, Rennard SI. Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 155: 1770-6.
135. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Xaubet A. Airway inflammation and microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 1015-22.
136. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 349-55.
137. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-20.
138. Maziak W, Loukides S, Culprit S, Sullivan P, Kharitonov SA, Barnes PJ. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 156: 998-1002.
139. Agusti AG, Villaverde JM, Togores B, Bosch M. Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 523-8.
140. Garcia-Aymerich J, Barreiro E, Farrero E, Marrades RM, Morero J, Anto GM. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J 2000; 16: 1037-42.
141. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646-52.
142. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in and expression of interleukin-5 protein in asthma and in exacerbation of chronic bronchitis. Clin Exp Allergy 1996; 26: 766-74.
143. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-7.
144. Sethi S. Bacterial infection and the pathogenesis of COPD. Chest 2000; 117: 286-91.
145. 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164: 358-64.
146. Peat JK, Woolcock AJ, and Cullen K. Decline of lung function and development of chronic airflow limitation: a longitudinal study of non-smokres and smokers in Busselton, Western Australia. Thorax 1989; 44: 31-7.
147. Townsend MC, DuChene AG, Morgan J, and Browner WS. Pulmonary function in relation to cigarette smoking and smoking cessation. Prev Med 1991; 20: 621-37.
148. Xu X, Dockery DW, Ware JH, Speizer FE, and Ferris BG Jr. Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. Am Rev Respir Dis 1992; 146: 1345-8.
149. Burchfiel CM, Marcus EB, Curb JD, Maclean CJ, Vollmer WM, et al. Effects of smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 1995; 151: 1778-85.
150. Krzyzanowski M, Robbins DR, Lebowitz MD. Smoking cessation and changes in respiratory symptoms in two populations followed for 13 years. Int J Epidemiol 1993; 22: 666-73.
151. Scanlon PD, Connett JE, Walter LA, Altose MD, Bailey XC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health study. Am J Respir Crit Care Med 2000; 161: 381-90.
152. Anthonisen NR, Connett JE, Enright PL, Manfreda J, and the Lung Health Study. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-9.
153. Young P, Dewse M, Fergusson W, Kolbe J. Improvements in outcomes for chronic obstructive pulmonary disease (COPD) attributable to a hospital-based respiratory rehabilitation programme. Aust N Z J Med 1999; 29: 59-65.
154. Willemse BWM, ten Hacken NHT, Rutgers B, Lesman-Leegle IGAT, Timens W, Postma DS. Smoking cessation improves direct and indirect airway hyperresponsiveness in COPD. Eur Respir J 2004, 24: 391-6.
155. Godtfredsen NS, Holst C, Prescott E, Vestbo J, Osler M. Smoking reduction, smoking cessation and mortality: a 16-year follow-up of 19, 732 men and women from the Copenhagen Centre for Prospective Study. Am J Epidemiol 2002; 156: 994-1001.